This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. IndicationJIDEYTRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who … Rx Insights from July ’26
The headline sounds scary. The reality is more nuanced. When “100% pharmaceutical tariff” started circulating in headlines, it was easy to imagine a world where common medications double in price overnight. That’s not what’s happening, at least not yet, and possibly not at all for most drugs. What happened: in April 2026, the federal government … Pharmaceutical Tariffs Are Here. Will Drug Prices Actually Go Up?
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. IndicationUTEBZI (tebipenem pivoxil) is FDA approved to treat complicated urinary tract infections (cUTI), including pyelonephritis, in adults with limited or no … Rx Insights from June ’26
Every year, you get the same notification from your PBM: “Here are your formulary changes and here is the member disruption.” That’s all. Most plan sponsors absorb the changes, notify their members, and move on. What they don’t get is the financial analysis behind why those decisions were made: not the net cost impact, not … Waiting for Your PBM to Tell You What Changed Isn’t a Strategy
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. IndicationLANGLARA (insulin glargine-aldy) is an FDA-approved biosimilar to Lantus and is indicated to improve glycemic control in adults and pediatric patients … Rx Insights from May ’26
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. Indication YUVIWEL (navepegritide) is FDA approved to increase linear growth in pediatric patients aged 2 years and older with achondroplasia and … Rx Insights from March ’26
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. Indication NEREUS (tradipitant) is a substance P/neurokinin-1 (NK-1) receptor antagonist indicated for the prevention of motion-induced vomiting in adults. Dosage and … RX Insights from January ’26
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. IndicationARMLUPEG (pegfilgrastim-unne) is an FDA-approved biosimilar to Neulasta (pegfilgrastim) indicated to reduce the risk of infection, as manifested by febrile neutropenia, in … RX Insights from December ’25
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. KYGEVVI Indication KYGEVVI is approved by the FDA for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric … Rx Insights from November ’25
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. KEYTRUDA QLEX Indication KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa) is approved for the treatment of 38 indications, including melanoma, non–small cell … Rx Insights from October ’25
Cigna’s announcement to shift away from prescription drug rebates for its fully insured plans in 2027 and for Express Scripts’ customers in 2028 is another signal of ongoing change in how pharmacy economics may be structured in the future. The transition from post-sale rebates to up-front discounts has the potential to redefine how value is measured … Cigna’s Plan to Shift from Drug Rebates: What it Could Mean for Pharmacy Strategy — and a Call to Action for Smarter Pharmacy Strategy
This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients. WAYRILZ Indication WAYRILZ (rilzabrutinib) is a kinase inhibitor approved by the FDA on August 29, 2025, for the treatment of adults … Rx Insights from September ’25
Expion Health, a pioneer in leveraging powerful technology and dynamic pricing strategies for healthcare cost containment, has been named to the esteemed CIO 100 Award list for 2024, honoring its groundbreaking ExpionIQ Advisor. For more than 25 years, the CIO 100 Awards have recognized innovative organizations around the world that exemplify the highest level of strategic … Expion Health Wins Prestigious CIO 100 Award
Today, Expion Health, a pioneer in leveraging powerful technology and dynamic pricing strategies, unveiled its new collaboration with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs). This strategic alliance will integrate Cost Plus Drugs’ revolutionary pricing into Expion Health’s product suite, offering an innovative way to tackle the escalating costs of specialty drugs.Karin … Expion Health and Mark Cuban Cost Plus Drug Company, PBC Forge Innovative Collaboration to Enhance Pharmacy Cost Management
Blue Shield’s shift from a single PBM to multiple specialized partners for pharmacy benefits management has health plans wondering if disaggregation is right for them. At Expion Health, we’re here to highlight why this shift matters and how we can support health plans like yours with this strategy. 1. Strategic Alignment: Partnering Without Conflict Moving … Blue Shield of California Pharmacy Shake-Up: 3 Disaggregation Considerations for Health Plans
The use of biosimilar products in lieu of originator biologic products has been a hot topic of discussion since the first FDA approval of Zarxio (a biosimilar for Neupogen) in 2015. Since then over 30 new biosimilars have been FDA approved but the biosimilar market hasn’t taken off as expected. The slower than expected uptake … The Impact of Humira Biosimilars: 5 Factors That Will Reduce Payer Costs
The biologics market could see some significant changes with the current and upcoming interchangeability approvals of several biosimilar products. Let’s dive into what biosimilars are and the importance of interchangeability. What is a biosimilar?A biosimilar is a potential alternative for an existing FDA-approved biologic. They are highly similar (can have minor differences in inactive components) … Biosimilars 101
